Organogenesis Holdings Inc (ORGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $104.24M
Last updated: Nov 17, 2026 at 4:10 PM ET
Organogenesis Holdings Inc (ORGO) Statistics
Organogenesis Holdings (ORGO) has a market cap of $104.24M and an enterprise value of $93.29M. It kept -38.45% of revenue as net income over the last 12 months. Revenue fell 24.33% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 10.51% below the market cap, as cash exceeds debt.
| Market Cap | $104.24M |
|---|---|
| Enterprise Value | $93.29M |
| Latest price (Nov 17, 2026) | $0.81 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.3x and 0.9x. Its year-end P/S ranged from 0.8x to 2.6x from 2019 to 2025.
| P/S Ratio | 0.3x |
|---|---|
| Forward P/S | 0.6x |
| P/B Ratio | 0.9x |
| P/TBV Ratio | 1.2x |
| P/OCF Ratio | 10.1x |
Price Statistics
The stock is down 86.70% over 52 weeks and trades 29.57% below its 50-day average.
| Beta (1Y) | 1.23 |
|---|---|
| 52-Week Change | -86.70% |
| 1-Month Change | -20.43% |
| 3-Month Change | -57.51% |
| 6-Month Change | -66.60% |
| 5-Year Change | -93.00% |
| Total Return (1Y) | -86.70% |
| Total Return (3Y CAGR) | -32.59% |
| Total Return (5Y CAGR) | -39.35% |
| Max Drawdown (1Y) | -87.39% |
| Max Drawdown (3Y) | -88.45% |
| Sharpe Ratio (1Y) | -2.80 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $1.15 |
| 200-Day Average | $2.19 |
| 52-Week Range | $0.73 to $5.91 |
| RSI (14 Days) | 37.7 |
| Average Volume (20 Days) | 1.13M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.32x current liabilities, and total debt is 0.09x shareholder equity.
| Current Ratio | 3.32x |
|---|---|
| Quick Ratio | 2.76x |
| Debt / Equity | 0.09x |
| Interest Coverage | -19.59x |
Returns and Efficiency
Return on invested capital is -66.28% over the last 12 months, against a 5-year average of 8.08%.
| Return on Equity (ROE) | -113.04% |
|---|---|
| Return on Assets (ROA) | -36.69% |
| Return on Invested Capital (ROIC) | -66.28% |
| ROE (5Y Average) | 11.86% |
| ROA (5Y Average) | 6.43% |
| ROIC (5Y Average) | 8.08% |
| Asset Turnover | 0.80x |
| Inventory Turnover | 4.33x |
| Receivables Turnover | 3.64x |
| Cash Conversion Cycle | 107 days |
Scores
ORGO has an Altman Z-Score of 0.44, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.44 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $352.05M over the last 12 months.
| Revenue | $352.05M |
|---|---|
| Revenue Growth (YoY) | -24.33% |
| Gross Profit | $230.79M |
| Operating Income | -$86.08M |
| Pretax Income | -$85.55M |
| Net Income | -$135.35M |
| EBITDA | -$63.03M |
| Reported EPS (TTM) | -$0.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 32.46% of the $368.90M in total assets.
| Cash and Equivalents | $21.33M |
|---|---|
| Total Debt | $10.37M |
| Net Cash | $10.95M |
| Net Cash Per Share | $0.08 |
| Working Capital | $110.48M |
| Shareholder Equity | $119.74M |
| Book Value Per Share | $0.93 |
| Tangible Book Value | $88.39M |
| Tangible Book Per Share | $0.69 |
| Total Assets | $368.90M |
| Total Liabilities | $106.16M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.36M of capital spending, operating cash flow left -$64.00K of free cash flow.
| Operating Cash Flow | $10.30M |
|---|---|
| Capital Expenditures | $10.36M |
| Free Cash Flow | -$64.00K |
| FCF Per Share | $0.00 |
| Depreciation and Amortization | $23.21M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -24.45%, against a 5-year average of 6.19%.
| Gross Margin | 65.56% |
|---|---|
| Operating Margin | -24.45% |
| Pretax Margin | -24.30% |
| Net Margin | -38.45% |
| EBITDA Margin | -17.90% |
| FCF Margin | -0.02% |
| Gross Margin (5Y Average) | 75.86% |
| Operating Margin (5Y Average) | 6.19% |
| Net Margin (5Y Average) | 6.30% |
Growth
Revenue grew 7.76% a year over 3 years, and EPS 17.43% a year.
| Revenue Growth (3Y CAGR) | +7.76% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.77% |
| EPS Growth (3Y CAGR) | +17.43% |
| EPS Growth (5Y CAGR) | +17.41% |
| Operating Income Growth (3Y CAGR) | +26.07% |
| Book Value Per Share Growth (2Y CAGR) | +3.64% |
| Tangible Book Per Share Growth (2Y CAGR) | +5.71% |
Dividends and Yields
ORGO does not pay a dividend. Its free cash flow yield is -0.06%.
| FCF Yield | -0.06% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 7 similar companies, ORGO has the lowest P/S.
P/S RatioPeer median 1.4x
ROICPeer median -11.66%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.06%
| P/S Ratio | 0.3x vs 1.4x median |
|---|---|
| ROIC | -66.28% vs -11.66% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -24.33% vs +10.06% median |
Analyst Forecast
Consensus estimates put revenue growth at -35.51% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -35.51% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ORGO
What is ORGO's market cap?
Organogenesis Holdings has a market cap of $104.24M. Its enterprise value, which adds debt and subtracts cash, is $93.29M.
How many shares of ORGO are outstanding?
Organogenesis Holdings has 128.99M shares outstanding. The count is up 1.66% from a year earlier.
Does ORGO pay a dividend?
No. Organogenesis Holdings does not pay a dividend.
How much debt does ORGO have?
Organogenesis Holdings has $10.37M of total debt and $21.33M of cash and equivalents, a net cash position of $10.95M.
ORGO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts